<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03429543</url>
  </required_header>
  <id_info>
    <org_study_id>1218-0091</org_study_id>
    <secondary_id>2016-000669-21</secondary_id>
    <nct_id>NCT03429543</nct_id>
  </id_info>
  <brief_title>Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM</brief_title>
  <official_title>A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin&#xD;
      dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10&#xD;
      to below 18 years and are currently taking metformin, insulin or both drugs (DINAMO TM) or&#xD;
      who are treatment na√Øve or not on active treatment after metformin withdrawal (DINAMO TM&#xD;
      MONO) .&#xD;
&#xD;
      Empagliflozin and linagliptin are both approved for use in adult patients with type 2&#xD;
      diabetes. This study will assess how well empagliflozin and linagliptin work by finding out&#xD;
      how these treatments affect blood glucose (sugar) levels compared to placebo (a pill that&#xD;
      contains no active drug), in children and adolescents. Empagliflozin and linagliptin are&#xD;
      considered investigational products in this study since while they have been approved for use&#xD;
      in adults, they have not been approved for children and adolescents due to lack of clinical&#xD;
      studies in this specific population.&#xD;
&#xD;
      Patients with type 2 diabetes have higher levels of blood glucose (sugar) than patients who&#xD;
      do not have this disease. The high level of sugar in the blood can lead to serious short-term&#xD;
      and long-term medical problems. The main goal of treating diabetic patients is to lower blood&#xD;
      glucose to a normal level. Lowering and controlling blood glucose help prevent or delay&#xD;
      complications of diabetes such as heart disease, kidney, eye and nerve diseases, and the&#xD;
      possibility of amputation.&#xD;
&#xD;
      Empagliflozin is a drug that helps to reduce blood glucose (sugar) levels by causing glucose&#xD;
      to be excreted in the urines.&#xD;
&#xD;
      Linagliptin works by increasing the production of insulin (a hormone that controls the level&#xD;
      of blood glucose) after meals when blood glucose (sugar) levels are too high. This helps to&#xD;
      lower blood sugar levels.&#xD;
&#xD;
      The subject will either receive one of the active study drugs or a placebo. This study will&#xD;
      be double blind; this means that neither the subject, nor the study doctor will know which&#xD;
      treatment the subject will receive.&#xD;
&#xD;
      Which treatment the subject receives is decided by a computer, purely by chance; this is&#xD;
      called a &quot;random assignment&quot;.&#xD;
&#xD;
      For this study, there will first be a screening visit, followed by a 2-week placebo run-in&#xD;
      period (all subjects will take placebo once daily). This run-in period is designed to ensure&#xD;
      subjects are able to take the study drugs as described in the study protocol. Thereafter&#xD;
      there will be a 26-week treatment phase (week 1-week 26) and a 26-week safety extension&#xD;
      period (week 27-week 52). Following this there will be a follow-up visit at week 55.&#xD;
&#xD;
      On Day 1 after the placebo run-in phase, the subject will be randomly assigned to receive one&#xD;
      of the 3 treatments: empagliflozin 10 mg, linagliptin 5 mg or placebo in a blinded manner.&#xD;
      This treatment will continue up to week 14. Then after week 14, the subject will be assigned&#xD;
      to receive one of the following 4 treatments: empagliflozin 10 mg, empagliflozin 25 mg,&#xD;
      linagliptin 5 mg or placebo in a blinded manner. The drugs assigned after week 14 will be the&#xD;
      same drugs as on Day 1 but some subjects will receive a higher dose of empagliflozin.&#xD;
&#xD;
      After the completion of the 26-week treatment period, the subject will enter a 26-week safety&#xD;
      extension period. The same active treatment that the subject had been assigned to at week 14&#xD;
      visit will be continued. Subjects assigned to placebo on Day 1 will be randomly assigned to&#xD;
      receive one of the 3 active treatments: empagliflozin 10 mg, empagliflozin 25 mg or&#xD;
      linagliptin 5 mg in a blinded manner. This safety extension period is primarily designed to&#xD;
      provide additional information on how well empagliflozin and linagliptin are tolerated.&#xD;
&#xD;
      Following the treatment phases, there will be a follow-up visit at week 55&#xD;
&#xD;
      Intervention model description:&#xD;
&#xD;
      Eligible subjects with HbA1c of 6.5% to 10.5% at screening will be randomized in a 1:1:1&#xD;
      ratio to receive empagliflozin 10 mg, linagliptin 5 mg or placebo. HbA1c assessment will be&#xD;
      performed at Week 12. All subjects with Week 12 HbA1c &lt; 7% will remain on previously assigned&#xD;
      randomized treatment. Subjects taking empagliflozin with Week 12 HbA1c &gt;= 7% will be&#xD;
      re-randomized in a 1:1 ratio to continue on the low dose treatment (empagliflozin 10 mg) or&#xD;
      up-titrate to the high dose treatment (empagliflozin 25 mg). Subjects taking linagliptin or&#xD;
      placebo with Week 12 HbA1c &gt;= 7% will remain on previously assigned treatment. All subjects&#xD;
      will get new medication kits dispensed at Week 14 to maintain the blinding.&#xD;
&#xD;
      At Week 26, all subjects previously assigned to placebo will be re-randomized in a 1:1:1:&#xD;
      ratio to receive one of the active treatments: empagliflozin 10 mg, empagliflozin 25 mg or&#xD;
      linagliptin 5 mg. All subjects will get new medication kits dispensed at Week 14 to maintain&#xD;
      the blinding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2018</start_date>
  <completion_date type="Anticipated">May 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 6, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DINAMO TM: Change from baseline in HbA1c (%)</measure>
    <time_frame>26 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>DINAMO TM Mono: Occurrence of treatment failure up to or at Week 26</measure>
    <time_frame>Up to 26 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM: Change from baseline in fasting plasma glucose (mg/dl)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM: Change from baseline in body weight (kg)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM: Change from baseline in systolic blood pressure (SBP)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM: Change from baseline in diastolic blood pressure (DBP)</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM: Proportion of patients who achieve HbA1c &lt; 6.5%</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM: Proportion of patients who achieve HbA1c &lt; 7.0%</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Time to treatment failure</measure>
    <time_frame>Up to 52 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Change in HbA1c (%) from baseline</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Change in FPG (mg/dL) from baseline</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Change in body weight (kg) from baseline</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Change in SBP (mmHg) from baseline</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Change in DBP (mmHg) from baseline</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono: Proportion of patients who achieve HbA1c &lt; 6.5%</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DINAMO TM Mono :Proportion of patients who achieve HbA1c &lt; 7.0%</measure>
    <time_frame>26 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin arm. Oral route. Linagliptin tablets administered once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin arm. Oral route. Start with a low dose of empagliflozin administered once daily and randomly up titrate to the high dose of empagliflozin administered once daily if HbA1c ‚â• 7% at week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm. Oral route. Placebo tablets administered once daily up to 26 weeks and then linagliptin or low dose of empagliflozin or high dose of empagliflozin administered once daily up to 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>Film Coated Tablet</description>
    <arm_group_label>Linagliptin</arm_group_label>
    <other_name>ONDERO, TRAJENTA, TRAYENTA, TRAZENTA, TRADJENTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Film Coated Tablet</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>JARDIANCE, JARDIANZ, GIBTULIO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film Coated Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 10 to 17 years (inclusive) at the time of randomisation (Visit 2)&#xD;
&#xD;
          -  Male and female patients&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be ready and able to use highly effective&#xD;
             methods of birth control per ICH M3 (R2) that result in a low failure rate of less&#xD;
             than 1% per year when used consistently and correctly. A list of contraception methods&#xD;
             meeting these criteria is provided in the patient's legal representative information&#xD;
             sheet.&#xD;
&#xD;
          -  Signed and dated written informed consent provided by the patient's parent(s) (or&#xD;
             legal guardian) and patient's assent in accordance with ICH-GCP and local legislation&#xD;
             prior to admission to the trial (informed assent will be sought according to the&#xD;
             patient's age, level of maturity, competence and capacity)&#xD;
&#xD;
          -  Documented diagnosis of T2DM at Visit 1A:&#xD;
&#xD;
               -  DINAMO TM: Documented diagnosis of T2DM for at least 8 weeks at Visit 1A&#xD;
&#xD;
               -  DINAMO TM Mono: Confirmation of T2DM at Visit 1A&#xD;
&#xD;
          -  Insufficient glycaemic control as measured by the central laboratory at Visit 1A:&#xD;
&#xD;
               -  DINAMO TM: HbA1c ‚â• 6.5% and ‚â§ 10.5%&#xD;
&#xD;
               -  DINAMO TM Mono: HbA1c ‚â• 6.5% and ‚â§ 9.0%&#xD;
&#xD;
          -  DINAMO TM: Patients treated with&#xD;
&#xD;
               -  diet and exercise plus metformin at a stable dose for 8 weeks prior to Visit 2 or&#xD;
                  not tolerating metformin (defined as patients who were on metformin treatment for&#xD;
                  at least 1 week and had to discontinue metformin due to metformin-related side&#xD;
                  effects as assessed by the investigator) AND/OR&#xD;
&#xD;
               -  diet and exercise plus stable basal or MDI insulin therapy,, defined as a weekly&#xD;
                  average variation of the basal insulin dose ‚â§ 0.1 IU/kg over 8 weeks prior to&#xD;
                  Visit 2. - DINAMOTM Mono: Drug-na√Øve patients or patients not on active treatment&#xD;
                  (including discontinuation of metformin due to intolerance [or previous&#xD;
                  discontinuation for other reasons] and/or discontinuation of insulin [insulin use&#xD;
                  must be 8 weeks or less] at investigator's discretion) prior to or at Visit 1A)&#xD;
&#xD;
          -  BMI ‚â• 85th percentile for age and sex according to WHO references at Visit 1B&#xD;
&#xD;
          -  Non-fasting serum C-peptide levels ‚â• 0.6 ng/ml as measured by the central laboratory&#xD;
             at Visit 1A&#xD;
&#xD;
          -  Compliance with trial medication intake must be between 75% and 125% during the&#xD;
             open-label placebo run-in period&#xD;
&#xD;
          -  Further inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history of acute metabolic decompensation such as diabetic ketoacidosis within 8&#xD;
             weeks prior to Visit 1A and up to randomisation (mild to moderate polyuria at the time&#xD;
             of randomisation is acceptable)&#xD;
&#xD;
          -  Diagnosis of monogenic diabetes (e.g. MODY)&#xD;
&#xD;
          -  History of pancreatitis&#xD;
&#xD;
          -  Diagnosis of metabolic bone disease&#xD;
&#xD;
          -  Gastrointestinal disorders that might interfere with study drug absorption according&#xD;
             to investigator assessment&#xD;
&#xD;
          -  Secondary obesity as part of a syndrome (e.g. Prader-Willi syndrome)&#xD;
&#xD;
          -  Any antidiabetic medication (with the exception of metformin and/or insulin background&#xD;
             therapy) within 8 weeks prior to Visit 1A and until Visit 2&#xD;
&#xD;
          -  Treatment with weight reduction medications (including anti-obesity drugs) within 3&#xD;
             months prior to Visit 1A and until Visit 2&#xD;
&#xD;
          -  History of weight-loss surgery or current aggressive diet regimen (according to&#xD;
             investigator assessment) at Visit 1A and until Visit 2&#xD;
&#xD;
          -  Treatment with systemic corticosteroids for &gt; 1 week within 4 weeks prior to Visit 1A&#xD;
             and up to Visit 2 Inhaled or topical use of corticosteroids (e.g. for asthma/chronic&#xD;
             obstructive pulmonary disease) is acceptable.&#xD;
&#xD;
          -  Change in dose of thyroid hormones within 6 weeks prior to Visit 1A or planned change&#xD;
             or initiation of such therapy before Visit 2&#xD;
&#xD;
          -  Known hypersensitivity or allergy to the investigational products or their excipients&#xD;
&#xD;
          -  Impaired renal function defined as estimated Glomerular Filtration Rate (eGFR) &lt; 60&#xD;
             ml/min/1.73m¬≤ (according to Zappitelli formula) as measured by the central laboratory&#xD;
             at Visit 1A&#xD;
&#xD;
          -  Indication of liver disease defined by serum level of either alanine transaminase&#xD;
             (ALT), aspartate transaminase (AST) or alkaline phosphatase above 3 fold upper limit&#xD;
             of normal (ULN) at Visit 1A as measured by the central laboratory at Visit 1A&#xD;
&#xD;
          -  History of belonephobia (needle phobia)&#xD;
&#xD;
          -  Any documented active or suspected malignancy or history of malignancy within 5 years&#xD;
             prior to Visit 1A, except appropriately treated basal cell carcinoma of the skin or in&#xD;
             situ carcinoma of uterine cervix&#xD;
&#xD;
          -  Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells (e.g.&#xD;
             malaria, babesiosis, haemolytic anaemia)&#xD;
&#xD;
          -  Any other acute or chronic medical or psychiatric condition or laboratory abnormality&#xD;
             that, based on investigator's judgement, would jeopardize patient safety during trial&#xD;
             participation or would affect the study outcome&#xD;
&#xD;
          -  Medical contraindications to metformin according to the local label (for patient on&#xD;
             metformin background therapy)&#xD;
&#xD;
          -  Patient not able or cannot be supported by his/her parent(s) or legal guardian to&#xD;
             understand and comply with study requirements based on investigator's judgement&#xD;
&#xD;
          -  Previous randomisation in this trial&#xD;
&#xD;
          -  Currently enrolled in another investigational device or drug trial, or less than 30&#xD;
             days since ending another investigational device or drug trial(s), or receiving other&#xD;
             investigational treatment(s)&#xD;
&#xD;
          -  Chronic alcohol or drug abuse within 3 months prior to Visit 1A or any condition that,&#xD;
             in the investigator's opinion, makes them an unreliable trial patient or unlikely to&#xD;
             complete the trial&#xD;
&#xD;
          -  Female patients who are pregnant, nursing, or who plan to become pregnant in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micah Olson</last_name>
      <phone>+001(602)9330935</phone>
      <email>molson@phoenixchildrens.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Wheeler</last_name>
      <phone>+001(520)626-6077</phone>
      <email>Mwheeler@peds.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHOC Childrens Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Daniels</last_name>
      <phone>+001(714)509-8634</phone>
      <email>mdaniels@choc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sejal Shah</last_name>
      <phone>+001(650)498-7351</phone>
      <email>sshah2@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gottschalk</last_name>
      <phone>+001(858)966-4032</phone>
      <email>mgottsch@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shylaja Srinivasan</last_name>
      <phone>+001(415)353-9084</phone>
      <email>shylaja.srinivasan@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petter Bjornstad</last_name>
      <phone>+001(720)777-9514</phone>
      <email>Petter.bjornstad@childrenscolorado.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Tamborlane</last_name>
      <phone>+001(203)785-4646</phone>
      <email>William.tamborlane@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh Nguyen</last_name>
      <phone>+001(904)619-8157</phone>
      <email>thanh.nguyen@jaxadvresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Empire Clinical Research, LLC</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oceane7 Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Gonzalez</last_name>
      <phone>+001(305)261-2738</phone>
      <email>e.gonzalez@oceane7.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric and Adult Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Desai</last_name>
      <phone>+001(407)271-4208</phone>
      <email>vsd59@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nemours Clinic</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude Desmangles</last_name>
      <phone>+001(850)505-4745</phone>
      <email>jean-claude.desmangles@nemours.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Rodriguez</last_name>
      <phone>+001(813)974-5529</phone>
      <email>hrodrig1@health.usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group, Pediatric Diabetes and Endocrinology at Winter Park</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konda Reddy</last_name>
      <phone>+001(407)896-2901</phone>
      <email>Konda.reddy.md@flhosp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Children's Center for Advanced Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Muir</last_name>
      <phone>+001(404)785-5437</phone>
      <email>abmuir@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Leichter</last_name>
      <phone>+001(706)322-1700</phone>
      <email>sleichter@iacthealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Tsalikian</last_name>
      <phone>+001(319)356-1833</phone>
      <email>Eva-tsalikian@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novak Center for Children's Health</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kupper Wintergerst</last_name>
      <phone>+001(502)852-4347</phone>
      <email>kawint01@louisville.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risa Wolf</last_name>
      <phone>+001(410)955-9773</phone>
      <email>Rwolf@jhu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Crocker</last_name>
      <phone>+001(617)355-7476</phone>
      <email>melissa.crocker@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Laffel</last_name>
      <phone>+001(617)732-2603</phone>
      <email>Lori.laffel@joslin.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Integrative Biosciences Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Buggs-Saxton</last_name>
      <phone>+001(313)832-9238</phone>
      <email>cbuggs@med.wayne.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naznin Dixit</last_name>
      <phone>+001(601)815-2005</phone>
      <email>ndixit@umc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Clements</last_name>
      <phone>+001(816)983-6982</phone>
      <email>maclements@cmh.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advantage Clinical Trials</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Guido</last_name>
      <phone>+001(917)962-0234</phone>
      <email>Gianguido2386@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Underland</last_name>
      <phone>+001(718)920-4664</phone>
      <email>lunderla@montefiore.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UBMD Pediatrics</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Bethin</last_name>
      <phone>+001(716)323-0170</phone>
      <email>kbethin@upa.chob.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Gallagher</last_name>
      <phone>+001(212)263-9910</phone>
      <email>Marypat.gallagher@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Weinstock</last_name>
      <phone>+001(315)464-5740</phone>
      <email>WEINSTOR@upstate.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Jain</last_name>
      <phone>+001(919)962-2796</phone>
      <email>nina_jain@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Wood</last_name>
      <phone>+001(216)844-1677</phone>
      <email>Jamie.wood@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minu George</last_name>
      <phone>+001(405)271-6764</phone>
      <email>minu-george@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jelley</last_name>
      <phone>+001(918)619-4815</phone>
      <email>david-jelley@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Huerta-Saenz</last_name>
      <phone>+001(717)531-7765</phone>
      <email>lhuertasaenz@pennstatehealth.psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Willi</last_name>
      <phone>+001(267)426-7037</phone>
      <email>willi@email.chop.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monument Health Rapid City Hospital, Inc.</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Edelen</last_name>
      <phone>+001(605)755-4326</phone>
      <email>rhcredelen@monument.health</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>LifeDoc Research, PLLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Velasquez-Mieyer</last_name>
      <phone>+001(901)921-7986</phone>
      <email>velasquez493@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Shoemaker</last_name>
      <phone>+001(615)343-8116</phone>
      <email>Ashley.H.Shoemaker@VUMC.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Office of Amir A. Hassan, MD, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Saenz Medical Center</name>
      <address>
        <city>La Joya</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Saenz</last_name>
      <phone>+001(956)585-1688</phone>
      <email>JSAENZ1643@AOL.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Lynch</last_name>
      <phone>+001(210)567-5283</phone>
      <email>lynchj2@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryce Nelson</last_name>
      <phone>+001(804)527-4713</phone>
      <email>Bryce.Nelson@vcuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende S.A.</name>
      <address>
        <city>Nueva C√≥rdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cl√≠nicas Pte. Dr. Nicol√°s Avellaneda</name>
      <address>
        <city>San Miguel de Tucum√°n</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mar√≠a Felipe Gacioppo</last_name>
      <phone>+5403814276008</phone>
      <email>verofelipe@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scentryphar Pesquisa Cl√≠nica Ltda</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Estudos e Pesquisas Cl√≠nicas IEP-CE</name>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Funda√ß√£o de Apoio ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da Faculdade de Medicina de Ribe</name>
      <address>
        <city>Ribeir√£o Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Dr. Consulta</name>
      <address>
        <city>S√£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Manitoba - Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Wicklow</last_name>
      <phone>204-787-7435</phone>
      <email>bwicklow@hsc.mb.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farid Mahmud</last_name>
      <phone>14168136218</phone>
      <email>farid.mahmud@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwei Du</last_name>
      <phone>+8643188786134</phone>
      <email>dhw_101@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feihong Luo</last_name>
      <phone>8602164931990</phone>
      <email>luofh@fudan.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Children'S Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Wei</last_name>
      <phone>86-0371-85515838</phone>
      <email>Haiyanwei2009@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Diabetes Cardiovascular IPS</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dexa-Diab IPS</name>
      <address>
        <city>Bogot√° DC</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>IPS Universitaria Servicio Salud - Universidad de Antioquia</name>
      <address>
        <city>Medell√≠n</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mart√≠n Toro Ramos</last_name>
      <phone>+573004229024</phone>
      <email>martoram1@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Otfried Schwab</last_name>
      <phone>+49(761)270-44821</phone>
      <email>karl.otfried.schwab@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendkrankenhaus auf der Bult</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torben Biester</last_name>
      <phone>+49(511)81150</phone>
      <email>biester@hka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Univ. Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Hershkovitz</last_name>
      <phone>97286403517/972-52-2629025</phone>
      <email>elih@bgu.ac.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naim Shehadeh</last_name>
      <phone>972-4-8542646</phone>
      <email>n_shehadeh@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center Tel Hashomer</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orit Hamiel</last_name>
      <phone>00972-3-5305015</phone>
      <email>orit.hamiel@sheba.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han-Wook Yoo</last_name>
      <phone>82230103374</phone>
      <email>hwyoo@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho-Seong Kim</last_name>
      <phone>82222282069</phone>
      <email>kimho@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Soon Hwang</last_name>
      <phone>82312195166</phone>
      <email>pedhwang@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigaci√≥n en Salud y Metabolismo S.C.</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CAIMED Investigacion en Salud, S.A. de C.V.</name>
      <address>
        <city>Ciudad de M√©xico</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Ram√≠rez Mendoza</last_name>
      <phone>+525565834651</phone>
      <email>drferramirez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigaci√≥n Metab√≥licos y Cardiovasculares, S.C.</name>
      <address>
        <city>Ciudad Madero</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Violante Ortiz</last_name>
      <phone>+528332142554</phone>
      <email>dr.violante@prodigy.net.mx</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico</name>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Barrientos Perez</last_name>
      <phone>+522223038350</phone>
      <email>marga_barrientos@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigacion Medica Sonora S.C.</name>
      <address>
        <city>Sonora</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaci√≥n M√©dica de Ocidente, S.C.</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Pelayo Orozco</last_name>
      <phone>+523312044280</phone>
      <email>drasusanapelayo@yahoo.com.mx</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APDP - Associa√ß√£o Protectora dos Diab√©ticos de Portugal</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo√£o Raposo</last_name>
      <phone>351213816179</phone>
      <email>filipe.raposo@apdp.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universit√°rio S√£o Jo√£o,EPE</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C√≠ntia Correia</last_name>
      <phone>+351225512100</phone>
      <email>cintiacastro-correia@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Juan Bautista School of Medicine</name>
      <address>
        <city>Caguas</city>
        <zip>00000</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Irizarry Gonzalez</last_name>
      <phone>+001(787)743-3038</phone>
      <email>endocrinologa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital 'The Badge of Honor Order'</name>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Bardymova</last_name>
      <phone>+73952467130</phone>
      <email>tpbardymova@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivanovo Reg.Clin.Hosp.</name>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Votyakova</last_name>
      <phone>+74932560589</phone>
      <email>olg-votyakova@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rep.childrens clin.hosp.</name>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Kovalenko</last_name>
      <phone>+7341268-42-03</phone>
      <email>tatkov18@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Medical University, Kazan</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farida Valeeva</last_name>
      <phone>+78432693427</phone>
      <email>val-farida@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Munic. Instit. of HC &quot;Kirov clin. hosp.#7 n.a.V.I.Urlova&quot;</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandr Sobolev</last_name>
      <phone>+78332566490</phone>
      <email>alexandersobolev@list.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology Scientific Center, MoH and Social Development</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Peterkova</last_name>
      <phone>+74991240266</phone>
      <email>peterkovava@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Novosibirsk Regional Clinical Hospital</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Bondar</last_name>
      <phone>+73833159921</phone>
      <email>keo@oblmed.nsk.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fed. State Budget Educational Instit. of Higher Education &quot;Rostov State Med. Univ.&quot; of MoH of RF</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galina Galkina</last_name>
      <phone>+79185475185</phone>
      <email>nvgalkin@rambler.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Pediatric University</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulia Skorodok</last_name>
      <phone>+79213063931</phone>
      <email>julia_skorodok@mail.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siberian State Med.Uni,Faculty Therapy Dep.w/ Clin.Pharmacol</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Samoilova</last_name>
      <phone>+7(382)253-04-23</phone>
      <email>samoilova_y@inbox.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bahkir state med. Univ. of the Ministry Polyclinic Pediatric</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Malievskiy</last_name>
      <phone>+79173445910</phone>
      <email>malievsky@list.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>BMA Medical College and Vajira Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swangjit Suraamornkul</last_name>
      <phone>+6622443490</phone>
      <email>swangjits@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pattara Wiromrat</last_name>
      <phone>+6643363664</phone>
      <email>patwiro@kku.ac.th</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rajavithi Hospital</name>
      <address>
        <city>Krung Thep Maha Nakhon</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2018</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

